Study finds fall in antibody activity – but scientists say jab should still protect against severe disease and death
A laboratory study suggests that the South African variant of the coronavirus may reduce antibody protection from the Pfizer/BioNTech vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies have said.
The study found the vaccine was still able to neutralise the virus and there is not yet evidence from trials in people that the variant reduces vaccine protection, the companies said.
